E-LIB Suche - Ergebnisse für: Phillips, Tycel J.

1

Taking a BiTE out of Lymphoma: Bispecific Antibodies in B-C..:

Weiss, Jonathan M. ; Phillips, Tycel J.
Cancers. 16 (2024) 9 - p. 1724 , 2024

Link: https://doi.org/10.3390/..

2

A phase 2 study of the PI3Kδ inhibitor parsaclisib in relap..:

Phillips, Tycel J. ; Avigdor, Abraham ; Gurion, Ronit...
Blood Advances. 8 (2024) 4 - p. 867-877 , 2024

Link: https://doi.org/10.1182/..

3

Contributors:

, In: Resistance to Anti-Cd20 Antibodies and Approaches for their Reversal,

Abdullahi, Hamisu ; Abubakar, Sharafudeen Dahiru ; Aliyu, Mansur... - p. xxi-xxiii , 2024

Link: https://doi.org/10.1016/..

4

Targeted therapies for follicular lymphoma:

, In: Resistance to Anti-Cd20 Antibodies and Approaches for their Reversal,

Takiar, Radhika ; Phillips, Tycel J. - p. 123-145 , 2024

Link: https://doi.org/10.1016/..

5

Polatuzumab vedotin, venetoclax, and an anti‐CD20 monoclona..:

Yuen, Sam ; Phillips, Tycel J. ; Bannerji, Rajat...
American Journal of Hematology. , 2024

Link: https://doi.org/10.1002/..

6

Improvements in Patient-Reported Outcomes in Relapsed or Re..:

Phillips, Tycel ; Lugtenburg, Pieternella ; Kalsekar, Anupama...
Clinical Lymphoma Myeloma and Leukemia. 24 (2024) 3 - p. e78-e87.e2 , 2024

Link: https://doi.org/10.1016/..

7

Acalabrutinib plus venetoclax and rituximab in treatment-na..:

Wang, Michael L ; Robak Prof., Tadeusz ; Maddocks, Kami J...
Blood Advances. , 2024

Link: https://doi.org/10.1182/..

8

Estimating long-term outcomes in classic Hodgkin lymphoma: ..:

Phillips, Tycel ; Migliaccio-Walle, Kristen ; Yu, Kristina S....
Leukemia & Lymphoma. 64 (2023) 5 - p. 1017-1025 , 2023

Link: https://doi.org/10.1080/..

9

Blockade of CCR1 induces a phenotypic shift in macrophages ..:

Le, Kang ; Sun, Jing ; Ghaemmaghami, Javid...
Blood Advances. 7 (2023) 15 - p. 3952-3967 , 2023

Link: https://doi.org/10.1182/..

10

PB1926: EFFICACY AND SAFETY OF ONCE DAILY (QD) VS TWICE DAI..:

Tam, Constantine ; Shadman, Mazyar ; Sharman, Jeff...
HemaSphere. 7 (2023) S3 - p. e70124b5 , 2023

Link: https://doi.org/10.1097/..

11

P628: UPDATED ANALYSIS OF BELLWAVE-001: A PHASE 1/2 OPEN-LA..:

Woyach, Jennifer ; Flinn, Ian W. ; Awan, Farrukh...
HemaSphere. 7 (2023) S3 - p. e7809236 , 2023

Link: https://doi.org/10.1097/..

12

Targeting MCL‐1 and BCL‐2 with polatuzumab vedotin and vene..:

Lasater, Elisabeth A. ; Amin, Dhara N. ; Bannerji, Rajat...
American Journal of Hematology. 98 (2023) 3 - p. 449-463 , 2023

Link: https://doi.org/10.1002/..

13

MCL-467 Glofitamab Monotherapy Induces High Complete Respon..:

Phillips, Tycel ; Dickinson, Michael ; Morschhauser, Franck...
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) - p. S462 , 2023

Link: https://doi.org/10.1016/..

14

Integrative analysis of clinicopathological features define..:

Vose, Julie M. ; Fu, Kai ; Wang, Lu...
Journal of Hematology & Oncology. 16 (2023) 1 - p. , 2023

Link: https://doi.org/10.1186/..

15

Adding venetoclax to lenalidomide and rituximab is safe and..:

Phillips, Tycel J. ; Bond, David ; Takiar, Radihka...
Blood Advances. 7 (2023) 16 - p. 4518-4527 , 2023

Link: https://doi.org/10.1182/..